Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARNET
2015-003370-33Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in hepatitis C virus infection, sponsored by AbbVie Inc. Primary endpoint: SVR12. Started Sep 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-003370-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003370-33.